11 results about "Digoxigenin" patented technology

This application relates to the technical field of biomarkers, and particularly to a preparation method and application of an RNA vector-related translocation complex; the translocation complex includes an RNA vector, and the RNA vector includes an RNA vector core sequence, a biotin-labeled primer, and a digoxigenin-labeled primer. The forward sequence of the RNA vector core sequence is shown in SEQ ID NO.1, and the reverse sequence of the RNA vector core sequence is shown in SEQ ID NO.2; through the RNA vector including the RNA vector core sequence, the biotin-labeled primer, and the digoxigenin-labeled primer, one end of the RNA vector is connected to streptomycin-coated magnetic beads through the biotin-labeled primer, and the other end is connected to the digoxigenin-treated glass surface, with firm binding. The RNA vector core region can form a translocation complex with the Holo-RdRp polymerase and the nsp13 helicase, and the single-molecule magnetic tweezer technology can effectively reflect the kinetic characteristics of the nsp13 reaction in real time.

The present invention relates to a humanized antibody having excellent binding affinity for digoxigenin and its uses. When using an antibody or an antigen-binding fragment thereof that specifically recognizes digoxigenin according to an embodiment of the present invention, it can be expected to regulate the concentration of a drug in vivo as needed or increase the half-life of the drug in a living body by means of a complex (DOligobody) containing the same.

The invention provides a novel SNP (Single Nucleotide Polymorphism) three-dimensional fluorescence in-situ hybridization detection probe and a detection method, and belongs to the technical field of gene detection, the probe comprises a hairpin structure and is composed of an annular sequence and a stem-loop sequence, 5'end and 3 'end chain segments of the stem-loop sequence are respectively modified with digoxin antigens, the digoxin antigens are combined with anti-digoxin antibodies with fluorescence report group clusters and quenching group clusters, and the digoxin antigens with fluorescence report group clusters and quenching group clusters are combined with digoxin antigens with fluorescence report group clusters and quenching group clusters. The tail end of the 3'end chain segment is connected with the primer through a non-reaction monomer. The detection method comprises the steps of sample collection and pretreatment, double-stranded nucleic acid melting, probe hybridization and signal generation, and fluorescence signal detection. The sensitivity is improved through multiple signal amplification, rapid detection is achieved without enzyme amplification, and the kit has high specificity, is easy and convenient to operate, high in cost benefit and wide in applicability and can be used for drug gene SNP detection and other scenes.

The present invention relates to small secreted reporter-peptides 15 to 150 amino-acids in length comprising a response element, activated by one or more transcription factors induced by the pharmacology active substance to be analyzed following its interaction with a specific intracellular or cell surface molecule, functionally linked to a response element, a TATA box, a signal peptide, anchor and detection sequences to which antibodies can be raised, and a poy-A tail. The anchor sequence may differ from one peptide to another or may be common to multiple secreted reporter-peptides such that all the peptides can be analyzed simultaneously by ELISA using a detection antibody labelled with for example HRP, or by the use of a commonly available immuno-detection platform such MSD, Gyros, AlphaLisa, or Biacore. The detection sequence is unique to each secreted reporter-peptide and may be labelled with a Sulfo-Tag that permits detection of the peptide on the MSD platform, or Alexa that permits detection on the Gyros platform, or digoxigenin that permits detection of on the PerkinElmer AlphaLISA platform, or left unlabeled for detection by SPR on a Biacore platform. The present invention provides i.a. a substantial improvement of cell-based assays for analysis using automated immune-detection platforms and allows simultaneous analysis of multiple analytes, multiple sampling from a single cell culture, and obviates the necessity to lyse cells and remove cell debris by centrifugation prior to analysis on an automated immuno-detection platform. The present invention also provides a means of increasing the dynamic range, sensitivity and reducing the cost of cell-based assays and can be applied to existing engineered cell lines, such as those containing a reporter-gene such as a luciferase reporter-gene obviating the necessity to extensively re-engineer cell lines containing multiple molecular constructs.

This invention relates to the field of chemical synthesis, specifically to a nucleotide analog, its preparation method, and its applications. The invention provides a nucleotide analog, its preparation method, and its applications. This nucleotide analog utilizes digoxigenin or biotin as a marker, achieving precise base recognition and high-sensitivity sequencing through binding to a specific enzyme system. Compared to currently widely used sequencing methods, it requires fewer copy numbers. Furthermore, G base quenching can be suppressed.

This invention relates to the field of biology, and particularly to a ligand-coupled microsphere for measuring inverse-locking levels, its preparation method, and a method for measuring inverse-locking levels. The ligand-coupled microsphere comprises a ligand coupled with a first label, a DNA fragment, and a polystyrene microsphere. A second label is coupled to one end of the DNA fragment, and the second label specifically binds to the first label. Digoxigenin is coupled to the other end of the DNA fragment. An anti-digoxigenin antibody is coupled to the surface of the polystyrene microsphere, and the polystyrene microsphere is linked to the DNA fragment via the anti-digoxigenin antibody and digoxigenin. The measurement method of this invention can measure different receptor-ligand interactions and enables its application in commercial instruments, forming a more universal inverse-locking measurement method. This allows inverse-locking measurements to be applied in more situations, providing theoretical support for the engineering modification of various receptors such as TCR, and providing data support for clinical applications.

The present invention discloses a DNA probe for detecting nucleic acids of pathogens of urogenital tract infections and its application. The pathogens of urogenital tract infections include Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. The DNA probe comprises probe H1 and probe H2. The DNA probe is mixed with a target sequence to undergo a catalytic hairpin self-assembly reaction. The 5' end of probe H1 is modified with digoxigenin, and the 5' end of probe H2 is modified with biotin. The present invention utilizes the DNA probe and target sequence to catalyze the hairpin self-assembly reaction, combined with an immunochromatographic test strip, to rapidly, highly sensitively, and specifically detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium in an isothermal, enzyme-free amplification environment.

The present invention belongs to the technical field of antibodies. Provided is an anti-digoxigenin antibody or an antigen-binding fragment thereof. The anti-digoxigenin antibody or antigen-binding fragment thereof has high affinity for digoxigenin; and can be used for detection of digoxigenin, sequencing, preparation of a product used for detecting digoxigenin, and preparation of a product used in sequencing.

The present invention relates to humanized antibodies having good binding ability to digoxigenin and uses thereof. When an antibody or antigen-binding fragment thereof specifically recognizing digoxigenin according to one aspect of the present invention is used, the concentration of the drug in the body is adjusted as needed through a complex (DOligobody) containing the same, or the concentration of the drug in vivo It is expected that the half-life can be increased.

The present invention relates to a novel proteasome inhibitor comprising a digoxigenin-derived lactone ring-based compound as an active ingredient, and can simultaneously exhibit high 20S proteasome inhibitory activity and low normal cell toxicity. The compound has excellent cancer cell selectivity, has pharmacological properties with improved anticancer effects and therapeutic indices, and can be useful for various carcinomas such as multiple myeloma, breast cancer, and hepatocellular carcinoma.

The invention discloses a kit for simultaneously detecting residual DNA of host cells in various biological products based on RPA-LFD and application thereof, the kit comprises specific primers and probes designed for residual DNA of Chinese hamster ovary cells (CHO), Escherichia coli cells (E.coli) or P.pastoris cells (P.pastoris), the 3'terminal of the probe is modified with Spacer C3, the 5 'terminal of the probe is modified with TAMRA, Digoxigenin and FAM respectively, and the specific primers and probes are used for detecting residual DNA of host cells in various biological products based on RPA-LFD. According to the present invention, the 5'terminal of the downstream primer is modified with Biotin, the RPA amplification temperature and the RPA amplification time are optimized, the detection time of the kit is only 15-30 min, the sensitivity is high, the whole process is performed in the 37 DEG C environment, the minimum 10 copies / [mu] L sample can be detected, the specificity is good, and compared with the existing fluorescent quantitative PCR detection method, the kit has advantages of high accuracy and fast detection speed, and can be widely used in the detection of the RPA. The method is of great significance to multiple rapid detection of residual DNA of host cells in biological products.